Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1995-06-05
1997-12-30
Loring, Susan A.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241301, 4241411, 4241581, 4241331, 4241341, 5303871, 5303873, 5303881, 53038823, 53038824, 53038885, 435325, 435328, 435335, 435336, 4353441, A61K 39395, C07K 1600, C07K 1626, C07K 1624
Patent
active
057027056
ABSTRACT:
Cleavage site blocking antibody that binds to prohormones, preferable Tumor Necrosis Factor, thereby preventing the formation of prohormone fragment(s) by proteolysis of the prohormone, and uses of the antibody including prophylactic and therapeutic methods to treat disease, and diagnostic assays for determining the amount of the prohormone and prohormone fragments present in a patients body.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4870163 (1989-09-01), Rubin et al.
patent: 5231024 (1993-07-01), Moeller et al.
Beutler, B. et al., Science, 229:869-871, 1985.
Fendley, B. M. et al, Hybridoma, 6(4):359-370, 1987.
Kriegler, M. et al, Cell, 53:45-53, Apr. 8, 1988.
Chistou, N.v. et al, Perspectives in Shock Research, 264:115-124, 1988.
Aggarwal et al., "Human Tumor Necrosis Factor," The Journal of Biological Chemistry, 260(4):2345-2354 (Feb. 25, 1985).
Bringman et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes," Hybridoma, 6(5):489-507 (1987).
Decker et al., "Cell-Associated Tumor Necrosis Factor (TNF) As A Killing Mechanism of Activated Cytotoxic Macrophages," The Journal of Immunology, 138(3):957-962 (Feb. 1, 1987).
Fendly et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6(4):359-370 (1987).
Jemmerson et al., "Monoclonal antibodies block the trypsin cleavage site on human placental alkaline phosphatase," FEBS 173(2):357-359 (Aug. 1984).
Kohler, et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, 256:495-499 (Aug. 7, 1975).
Kriegler et al., "A Novel Form of TNF/Cachectin Is A Cell Surface Cytotoxic Transmembrane Protein: Ramifications for the Complex Physiology of TNF," Cell, 53:45-53 (Apr. 8, 1988).
Milstein, C., et al., Immun. Today, 5(10):299-304 (1984).
Pennica et al., "Human tumor necrosis factor: precursor strcture, expression and homology to lymphotoxin," Nature, 312:724-729 (Dec. 1984).
Scuderi, P., "Suppression of Human Leukocyte Tumor Necrosis Factor Secretion by the Serine Protease Inhibitor .rho.-Toluenesulfonyl-L-Arginine Methyl Eser (TAME)", The Journal of Immunology, 143(1):168-173 (Jul. 1, 1989).
Shimamoto et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," Immunology Letters, 17:311-318 (1988).
Socher et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor," Proc. Natl. Acad. Sci. USA, 84:8829-8833 (Dec. 1987).
Steiner et al., "Use of a synthetic peptide antigen to generate antisera reactive with a proteolytic processing site in native human proinsulin: Demonstration of cleavage within clathrin-coated (pro)secretory vesicle," Proc. Natl. Acad. Sci. USA, 84:6184-6188 (Sep. 1987).
Tooze et al., "An Antibody Specific for an Endoproteolytic Cleavage Site Provides Evidence That Pro-opiomelanocortin Is Packaged Into Secretory Granules in AtT20 Cells before Its Cleavage," The Journal fo Cell Biology, 105:155-162 (1987).
Tracy et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," Nature, 330:662-664 (Dec. 17, 1987).
Kriegler Michael
Perez Carl
Blackburn Robert P.
Chiron Corporation
Loring Susan A.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
Antibody methods for the treatment of a hormone-mediated disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody methods for the treatment of a hormone-mediated disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody methods for the treatment of a hormone-mediated disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-199991